Pyxis Oncology (PYXS) Other financing activities (2020 - 2024)

Pyxis Oncology (PYXS) posted quarterly Other financing activities of $3000.0 for Q4 2024, down 93.75% quarter-over-quarter from $48000.0 in Q2 2024.

Pyxis Oncology (PYXS) Other financing activities (2020 - 2024) Analysis & Trends

Pyxis Oncology (PYXS) has reported Other financing activities for 5 consecutive years, with $3000.0 the latest figure, recorded in Q4 2024.

In Q4 2024, Other financing activities changed N/A year-over-year to $3000.0; the TTM figure through Dec 2024 stood at $296000.0 (up 140.65% YoY), while the FY2025 annual figure was $632000.0, up 113.51% from the prior year.
Other financing activities eased to $3000.0 in Q4 2024 per PYXS's latest filing, from $48000.0 in the prior quarter.
Across five years, Other financing activities topped out at $152.3 million in Q4 2021 and bottomed at $1000.0 in Q2 2022.
Historically, Other financing activities has averaged $17.9 million across 5 years, with a median of $117000.0 in 2023.
Annual changes were most pronounced in 2021 — Other financing activities jumped 1803.52% — and 2023, when it surged 1850.0%.
Pyxis Oncology's Other financing activities stood at $8.0 million in 2020, then surged by 1803.52% to $152.3 million in 2021, then tumbled by 100.0% to $6000.0 in 2022, then soared by 1850.0% to $117000.0 in 2023, then plunged by 97.44% to $3000.0 in 2024.
Business Quant data shows PYXS's Other financing activities at $3000.0 in Q4 2024, $48000.0 in Q2 2024, and $245000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Pyxis Oncology	198.37 Mn	165.38 Mn	-

Download Data